Phase 3 Type 2 Diabetes Trial, Recruiting NCT07093476 Sponsor: Celltrion Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Phase 3 Type 2 Diabetes Trial, Recruiting

NCT07093476
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are adults at the time they sign the consent form to join the study
  • People who have signed a written consent form voluntarily after being fully informed about the study's goals, methods, and potential effects
  • People who have been diagnosed with type 2 diabetes (a condition where the body does not use insulin properly)

Who may not be able to join:

  • People who have been diagnosed with a type of diabetes other than type 2 diabetes
  • People who have had a serious allergic reaction to the study drug, similar drugs, or the other medications used as part of the treatment in this trial
  • People whose serious diabetes-related health complications are not well controlled

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 6 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +82 3403 9647

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Celltrion
Registry
ClinicalTrials.gov
Start date
18 July 2025
Est. completion
1 December 2026

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

HbA1c

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov